CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis
Résumé
Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed at describing and quantifying the influence of CD4+ count depletion on the concentration-response relationship of rituximab in RA patients.